Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan, with operations spanning North America, Europe, Asia-Pacific, Latin America and the Middle East. Formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has since established a solid presence in prescription drug research, development and commercialization. The company focuses on advancing therapies in oncology, urology, immunology, nephrology and neuroscience, aiming to deliver innovative solutions that address unmet medical needs.
Astellas’ product portfolio includes treatments for a wide range of conditions. Its oncology franchise features Xtandi (enzalutamide) for prostate cancer and PADCEV (enfortumab vedotin-ejfv) for urothelial cancer, both of which have become cornerstones of the company’s cancer pipeline. In urology, the company markets Myrbetriq (mirabegron) and Vesicare (solifenacin) to manage overactive bladder symptoms. Immunosuppressants such as Prograf (tacrolimus) and Astagraf XL also play key roles in the company’s offerings for organ transplant recipients.
Research and development is central to Astellas’ growth strategy. The company invests in next-generation modalities including gene therapy, cell therapy and targeted radiopharmaceuticals. Astellas maintains a network of research centers and partnerships worldwide to accelerate discovery and clinical trials, with a particular emphasis on precision medicine and regenerative solutions. This commitment to R&D has yielded a robust pipeline of investigational compounds across multiple therapeutic areas.
Under the leadership of President and CEO Naoki Okamura, Astellas aims to strengthen its global footprint and foster collaboration with academic institutions, biotech firms and healthcare providers. The management team emphasizes corporate responsibility, sustainability and patient-centric initiatives, ensuring that the company’s innovations contribute to better health outcomes and social value around the world.
AI Generated. May Contain Errors.
Free ALPMY Stock Alerts